Axsome Acquires Global Rights to TAK-063 from Takeda for Schizophrenia and Tourette Syndrome Treatment

Axsome Therapeutics has acquired exclusive global rights to TAK-063, a novel PDE10A inhibitor, from Takeda Pharmaceutical. The acquisition expands Axsome's CNS portfolio and plans to develop the selective inhibitor for schizophrenia and Tourette syndrome. Phase 3 trial-enabling activities for schizophrenia are expected to begin in 2026. Takeda received an upfront payment and is eligible for additional payments related to development, regulatory, and commercial milestones, as well as royalties on potential global net sales.